ClinicalTrials.gg
Active, not recruitingNCT06298552ADAPT SERONUpdated Aug 10, 2026Results posted

A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis

A Phase 3 interventional study of Efgartigimod IV and Placebo IV in Generalized Myasthenia Gravis, gMG and Myasthenia Gravis, Generalized, sponsored by argenx. Active, not recruiting at 91 sites in 22 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by argenx · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
119
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 20 studies testing efgartigimod alfa in Myasthenia Gravis — 11 open to participants now, 14 under way, 7 of them phase 3. efgartigimod alfa · Myasthenia Gravis.

Enrollment
5th of 20
119 · median 55
Started
2024
with 4 others
Phase 3
10 of 20
3 open now
Primary completion
2025-06
later than 2 of 13 live
Registered
9th of 20
by date
Lead sponsor
12 of 20
argenx

Among the 20 studies testing efgartigimod alfa in Myasthenia Gravis, this one is the 5th largest by enrollment, is one of 5 that started in 2024, is one of 10 in phase 3, reaches primary completion later than 2 of the 13 other live ones, and was the 9th registered.

Myasthenia Gravis

331 studies on the registry are indexed under Myasthenia Gravis; 144 are open to participants now.

Browse Myasthenia Gravis studies →

Open to participants now

11 of the 20 studies testing efgartigimod alfa in Myasthenia Gravis are open now, in 12 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About efgartigimod alfa

efgartigimod alfa: first FDA approval 2021 (VYVGART), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing efgartigimod alfa in Myasthenia Gravis, or all of them as a file.
02

Study summary

The primary purpose of this study is to measure the efficacy and safety of efgartigimod IV compared to placebo in participants with Acetylcholine Receptor Binding Antibody (AChR-Ab) seronegative Generalized Myasthenia Gravis (gMG). The study consists of a Part A where participants will be randomized to receive either efgartigimod IV or placebo IV and a Part B where participants completing part A will receive open-label efgartigimod IV. Participants will be in the study for up to (approximately) 3.5 years.

03

Conditions studied

  • Generalized Myasthenia Gravis
  • gMG
  • Myasthenia Gravis, Generalized
  • Myasthenia Gravis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The participant is at least 18 years of age and the local legal age of consent for clinical studies when signing the ICF.
  • The participant is capable of providing signed and following with protocol requirements.
  • The participant agrees to use measures consistent with local regulations and the women of (WOCBP) must have a negative serum pregnancy test result at screening and a negative urine pregnancy test result at baseline before receiving the study drug.
  • The participant has no known weakness in infancy and later develop fatigable weakness after aged 16 years and diagnosed with acquired gMG of both of the following:

    1. History of abnormal neuromuscular transmission demonstrated by single fiber electromyography or repetitive nerve stimulation (RNS) or is for anti-muscle-specific kinase antibodies (MuSK-Ab) seropositive
    2. Either a history of positive edrophonium chloride test OR a demonstrated improvement in MG signs with treatments such as oral acetylcholinesterase (AChE) inhibitors, plasma exchange (PLEX), immunoabsorption, or intravenous immunoglobulin (IVIg)/ subcutaneous immunoglobulin (SCIg) treatment
  • The participant is receiving a stable dose of MG therapy before screening, including acetylcholinesterase (AChE) inhibitors, , or nonsteroidal therapies (NSISTs) in combination or alone

Exclusion criteria

Exclusion Criteria:

  • Known disease or any medical condition that would interfere with an accurate assessment of clinical symptoms of gMG or puts the participant at undue risk
  • History of , cancer, unless considered cured by adequate treatment with no evidence of recurrence for ≥3 years. Adequately treated participants with the following cancers can be included at any time: Basal cell or squamous cell skin cancer, Carcinoma in situ of the cervix, Carcinoma in situ of the breast, Incidental histological findings of prostate cancer
  • active infection that is not sufficiently resolved in the investigator's opinion or positive serum test at screening for active infection with any of the following: virus (HBV), virus (HCV),
  • History of or current alcohol, drug, or medication abuse as assessed by the investigator
  • Pregnant or lactating state or intention to become pregnant during the study
  • Live or received \<4 weeks before screening
  • Worsening muscle weakness secondary to concurrent infections or medications
  • Received a thymectomy less than 3 months before screening or thymectomy is planned during the study

The complete list of exclusion criteria can be found in the protocol.

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
119 participants (actual)

Study arms

  • Experimental
    Efgartigimod IV

    Patients receiving efgartigimod IV in both part A and part B

    Biological: Efgartigimod IV

  • Placebo comparator
    Placebo

    Patients receiving placebo during part A and receiving efgartigimod IV during part B

    Biological: Efgartigimod IV · Other: Placebo IV

Interventions

  • BiologicalEfgartigimod IV

    Intravenous infusion of efgartigimod

  • OtherPlacebo IV

    Intravenous infusion of placebo

06

What researchers measure

Primary outcomes

  1. MG-ADL Total Score Change From Baseline

    The Myasthenia Gravis Activities of Daily Living (MG-ADL) scale is an 8-item instrument used to assess MG symptoms and their effects on daily activities. The total score ranges from 0 (no symptoms) to 24 (most severe symptoms).

    Time frame: Up to 29 days in part A

Secondary outcomes

  1. QMG Total Score Change From Baseline

    The Quantitative Myasthenia Gravis (QMG) score includes 13 items that measure endurance or fatigability and accounts for fluctuations in disease state. The total score ranges from 0 (no symptoms) to 39 (highest disease severity).

    Time frame: Up to 29 days in part A

  2. Proportion of Participants Who Are Both MG-ADL and QMG Responders in Part A

    A participant was an MG-ADL responder if there was a ≥2-point reduction in the MG-ADL total score compared with baseline that was maintained for at least 4 consecutive weeks (ie, at least 5 consecutive visits total), with the first reduction occurring no later than 1 week after the last administration of IMP in part A. A participant was a QMG responder if there was a ≥3-point reduction in the QMG total score compared with baseline that was maintained for at least 4 consecutive weeks (ie, at least 5 consecutive visits total), with the first reduction occurring no later than 1 week after the last administration of IMP in part A.

    Time frame: Up to 8 weeks (part A)

  3. Proportion of Participants With MSE

    Minimal symptom expression (MSE) is defined as an MG-ADL total score of 0 or 1

    Time frame: Up to 8 weeks (part A) + 3 years (part B)

  4. Proportion of Participants Who Are MG-ADL Responders in Part A

    The Myasthenia Gravis Activities of Daily Living (MG- ADL) scale is an 8-item instrument used to assess MG symptoms and their effects on daily activities. The total score ranges from 0 (no symptoms) to 24 (most severe symptoms). A participant was an MG-ADL responder if there was a ≥2-point reduction in the MG-ADL total score compared with baseline that was maintained for at least 4 consecutive weeks (ie, at least 5 consecutive visits total), with the first reduction occurring no later than 1 week after the last administration of IMP in part A.

    Time frame: Up to 8 weeks (part A)

  5. Proportion of Participants Who Are QMG Responders in Part A

    The Quantitative myasthenia gravis (QMG) includes 13 items that measure endurance or fatigability and accounts for fluctuations in disease state. The total score ranges from 0 (no symptoms) to 39 (highest disease severity). A participant was a QMG responder if there was a ≥3-point reduction in the QMG total score compared with baseline that was maintained for at least 4 consecutive weeks (ie, at least 5 consecutive visits total), with the first reduction occurring no later than 1 week after the last administration of IMP in part A.

    Time frame: Up to 8 weeks (part A)

  6. Proportion of Participants Who Are Early MG-ADL Responders in Part A

    The Myasthenia Gravis Activities of Daily Living (MG- ADL) scale is an 8-item instrument used to assess MG symptoms and their effects on daily activities. The total score ranges from 0 (no symptoms) to 24 (most severe symptoms). An Early MG-ADL responder is an MG-ADL responder who had an onset of an MG-ADL response no later than 2 weeks after the first administration of IMP in part A.

    Time frame: Up to 8 weeks (part A)

  7. MG-ADL Total Score Change From Baseline Over Time in Part A and Part A+B

    The Myasthenia Gravis Activities of Daily Living (MG- ADL) scale is an 8-item instrument used to assess MG symptoms and their effects on daily activities. The total score ranges from 0 (no symptoms) to 24 (most severe symptoms).

    Time frame: Up to 8 weeks (part A) + 3 years (part B)

  8. MG-QoL15r Change From Baseline Over Time in Part A and Part A+B

    The Myasthenia Gravis Quality of Life-15 revised (MG-QoL15r) is a patient-reported instrument that measures the impact of MG symptoms on quality of life. The total scores range from 0 (best outcome) to 30 (worst outcome).

    Time frame: Up to 8 weeks (part A) + 3 years (part B)

  9. EQ-5D-5L VAS Change From Baseline Over Time in Part A and Part A+B

    The EQ-5D-5L is a participant-reported measure of health status developed by the EuroQol Group. The questionnaire comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Current health status is rated on vertical visual analog score (VAS) from 0 to 100, with a score of 0 corresponding to "the worst health you can imagine" and 100 corresponding to "the best health you can imagine."

    Time frame: Up to 8 weeks (part A) + 3 years (part B)

  10. Total IgG Concentrations Percent Changes From Baseline Over Time in Part A and Part A+B

    Time frame: Up to 8 weeks (part A) + 3 years (part B)

07

Results

Posted Aug 10, 2026
Limitations and caveats
As the study is ongoing at the time of the results reporting deadline, the submitted results are limited to primary outcome and part A safety data. Remaining results (part B) will be reported within a year of global study completion.

Participant flow

This study was conducted at 109 sites across 20 countries. A total of 245 participants were screened, of whom 119 were randomized following approval by a diagnostic adjudication committee. Participants who were historically MuSK seropositive were not adjudicated. As the study is ongoing at the time of the results reporting deadline, the submitted results are limited to primary outcome and part A safety data. Remaining results (part B) will be reported within a year of global study completion.

Participant flow — Overall Study
MilestoneEfgartigimod IVPlacebo
Started5861
Completed5460
Not completed41
Withdrew: Withdrawal by subject20
Withdrew: Meeting a protocol-specified criterion10
Withdrew: Withdrawal of consent10
Withdrew: Death01

Outcome measures

PrimaryMG-ADL Total Score Change From Baseline

The Myasthenia Gravis Activities of Daily Living (MG-ADL) scale is an 8-item instrument used to assess MG symptoms and their effects on daily activities. The total score ranges from 0 (no symptoms) to 24 (most severe symptoms).

Time frame:
Up to 29 days in part A
Reported as:
Least squares mean · points on a scale
MG-ADL Total Score Change From Baseline
points on a scaleEfgartigimod IVPlacebo
MG-ADL Total Score Change From Baseline-3.35 (-3.98 to -2.72)-1.90 (-2.51 to -1.28)
SecondaryQMG Total Score Change From Baseline

The Quantitative Myasthenia Gravis (QMG) score includes 13 items that measure endurance or fatigability and accounts for fluctuations in disease state. The total score ranges from 0 (no symptoms) to 39 (highest disease severity).

Time frame:
Up to 29 days in part A

Results for this outcome have not been posted.

SecondaryProportion of Participants Who Are Both MG-ADL and QMG Responders in Part A

A participant was an MG-ADL responder if there was a ≥2-point reduction in the MG-ADL total score compared with baseline that was maintained for at least 4 consecutive weeks (ie, at least 5 consecutive visits total), with the first reduction occurring no later than 1 week after the last administration of IMP in part A. A participant was a QMG responder if there was a ≥3-point reduction in the QMG total score compared with baseline that was maintained for at least 4 consecutive weeks (ie, at least 5 consecutive visits total), with the first reduction occurring no later than 1 week after the last administration of IMP in part A.

Time frame:
Up to 8 weeks (part A)

Results for this outcome have not been posted.

SecondaryProportion of Participants With MSE

Minimal symptom expression (MSE) is defined as an MG-ADL total score of 0 or 1

Time frame:
Up to 8 weeks (part A) + 3 years (part B)

Results for this outcome have not been posted.

SecondaryProportion of Participants Who Are MG-ADL Responders in Part A

The Myasthenia Gravis Activities of Daily Living (MG- ADL) scale is an 8-item instrument used to assess MG symptoms and their effects on daily activities. The total score ranges from 0 (no symptoms) to 24 (most severe symptoms). A participant was an MG-ADL responder if there was a ≥2-point reduction in the MG-ADL total score compared with baseline that was maintained for at least 4 consecutive weeks (ie, at least 5 consecutive visits total), with the first reduction occurring no later than 1 week after the last administration of IMP in part A.

Time frame:
Up to 8 weeks (part A)

Results for this outcome have not been posted.

SecondaryProportion of Participants Who Are QMG Responders in Part A

The Quantitative myasthenia gravis (QMG) includes 13 items that measure endurance or fatigability and accounts for fluctuations in disease state. The total score ranges from 0 (no symptoms) to 39 (highest disease severity). A participant was a QMG responder if there was a ≥3-point reduction in the QMG total score compared with baseline that was maintained for at least 4 consecutive weeks (ie, at least 5 consecutive visits total), with the first reduction occurring no later than 1 week after the last administration of IMP in part A.

Time frame:
Up to 8 weeks (part A)

Results for this outcome have not been posted.

SecondaryProportion of Participants Who Are Early MG-ADL Responders in Part A

The Myasthenia Gravis Activities of Daily Living (MG- ADL) scale is an 8-item instrument used to assess MG symptoms and their effects on daily activities. The total score ranges from 0 (no symptoms) to 24 (most severe symptoms). An Early MG-ADL responder is an MG-ADL responder who had an onset of an MG-ADL response no later than 2 weeks after the first administration of IMP in part A.

Time frame:
Up to 8 weeks (part A)

Results for this outcome have not been posted.

SecondaryMG-ADL Total Score Change From Baseline Over Time in Part A and Part A+B

The Myasthenia Gravis Activities of Daily Living (MG- ADL) scale is an 8-item instrument used to assess MG symptoms and their effects on daily activities. The total score ranges from 0 (no symptoms) to 24 (most severe symptoms).

Time frame:
Up to 8 weeks (part A) + 3 years (part B)

Results for this outcome have not been posted.

SecondaryMG-QoL15r Change From Baseline Over Time in Part A and Part A+B

The Myasthenia Gravis Quality of Life-15 revised (MG-QoL15r) is a patient-reported instrument that measures the impact of MG symptoms on quality of life. The total scores range from 0 (best outcome) to 30 (worst outcome).

Time frame:
Up to 8 weeks (part A) + 3 years (part B)

Results for this outcome have not been posted.

SecondaryEQ-5D-5L VAS Change From Baseline Over Time in Part A and Part A+B

The EQ-5D-5L is a participant-reported measure of health status developed by the EuroQol Group. The questionnaire comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Current health status is rated on vertical visual analog score (VAS) from 0 to 100, with a score of 0 corresponding to "the worst health you can imagine" and 100 corresponding to "the best health you can imagine."

Time frame:
Up to 8 weeks (part A) + 3 years (part B)

Results for this outcome have not been posted.

SecondaryTotal IgG Concentrations Percent Changes From Baseline Over Time in Part A and Part A+B
Time frame:
Up to 8 weeks (part A) + 3 years (part B)

Results for this outcome have not been posted.

Adverse events

Collected over Available data included for Part A (up to 8 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Efgartigimod IV1/58 (1.7%)3/58 (5.2%)16/58 (27.6%)
Placebo1/61 (1.6%)1/61 (1.6%)14/61 (23%)
Most frequent serious events
Most frequent serious events
EventEfgartigimod IVPlacebo
ANAEMIABlood and lymphatic system disorders1/580/61
DIVERTICULUM INTESTINALGastrointestinal disorders1/580/61
LOWER GASTROINTESTINAL HAEMORRHAGEGastrointestinal disorders1/580/61
UPPER GASTROINTESTINAL HAEMORRHAGEGastrointestinal disorders1/580/61
LOWER RESPIRATORY TRACT INFECTIONInfections and infestations1/580/61
MYASTHENIA GRAVISNervous system disorders1/580/61
MYASTHENIA GRAVIS CRISISNervous system disorders0/581/61
Most frequent other events
Most frequent other events
EventEfgartigimod IVPlacebo
HEADACHENervous system disorders3/587/61
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations5/583/61
FATIGUEGeneral disorders2/585/61
NAUSEAGastrointestinal disorders4/583/61
URINARY TRACT INFECTIONInfections and infestations3/583/61

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Efgartigimod IVPlaceboTotal
Mean50.6 ± 13.4451.7 ± 12.9751.2 ± 13.16
Sex: Female, Male
Sex: Female, Male(Participants)Efgartigimod IVPlaceboTotal
Female444690
Male141529
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Efgartigimod IVPlaceboTotal
Hispanic or Latino426
Not Hispanic or Latino5355108
Unknown or Not Reported134
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Efgartigimod IVPlaceboTotal
Asian8816
Black or African American123
White484694
Other145
08

Study locations

91 sites
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2024 to primary completion in Jun 2025, 14 months.

Results were first posted in Aug 2026, 1 year 1 month after primary completion.

Of 43 industry-sponsored phase 3 interventional studies under Myasthenia Gravis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 39. This study's 14 months is below that.

Counting every sponsor, half of 52 studies reached it within 30 months; a quarter within 20 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2024
First posted
Mar 7, 2024
StartActual
Apr 16, 2024
Primary completionActual
Jun 30, 2025
CompletionEst.
Jun 2028
Results first posted
Aug 10, 2026
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06298552
Lead sponsor
argenx
Responsible party
Sponsor
First posted
Mar 7, 2024
Start date
Apr 16, 2024
Primary completion
Jun 30, 2025
Completion
Jun 2028 (estimated)
Results posted
Aug 10, 2026
Last update
Aug 10, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Efgartigimod alfa

Start the discussion